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Abstract: The effect of thiazolidinediones (TZDs) on the progression of atherosclerosis in 
diabetes patients remains unclear. There has been heightened interest in recent years in this 
class of diabetes medications due to the non-glycemic lowering effects, such as altering lipids, 
inflammation and hematologic profiles. There have been several exciting studies over the past 
few years focused on the mechanism of action of the TZDs with respect to alteration in the 
cardio-metabolic profile in diabetes patients. New tools such as intravascular ultrasound have 
been used to follow plaques characteristics over time on a much more sensitive scale than has 
ever been possible in the past by coronary angiograms. These advances have enabled researchers 
to follow closely the macrovascular effects of different anti-atherosclerotic medications such as 
statins and TZDs. This article reviews the pathophysiology of atherosclerosis in diabetes, the 
role that TZDs play in this process and the imaging trials looking at the progression or regres-
sion of atherosclerosis in patients treated with TZDs.
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Introduction
The purpose of this review is to address many of the controversies surrounding the 
affects of glitazones and coronary atherosclerosis. The impact of thiazolidinedio-
nes (TZDs) and their ability to alter the progression of atherosclerosis in diabetics 
remains unclear. As the prevalence of diabetes increases, the burden of atherosclerosis 
is increasing at an alarming rate. The Center for Disease Control (CDC) now projects 
that by 2050 nearly 50 million people will be diagnosed with diabetes, up from their 
prior estimate of 39 million released just 2 years earlier. The largest impact will be 
seen in minority groups, with an expected increase of 481% in Hispanics and 208% 
in blacks.1 An analysis of the Framingham Heart Study by Fox et al demonstrated 
that the lifetime risk for cardiovascular disease is increased among individuals with 
obesity and diabetes, with a 78.8% lifetime risk in women and an 86.9% risk in men.2 
Overall, obesity alone was found to carry an additional 20% risk for the development 
of cardiovascular disease (CVD), compared to normal weight individuals. Prior studies 
have estimated that the lifetime risk of diabetes increases in proportion to BMI, rang-
ing from 7.6% among underweight individuals to as high as 74.4% among individuals 
with stage 2 obesity3 (Figure 1).
Patients with diabetes have a significant increase in the risk of advanced 
cardiovascular disease. Over a period of 18 years, Juutilainen et al studied 2301 patients 
with and without diabetes who were all free of CVD at baseline.4 50% of subjects with 
type 1 diabetes, 68% of subjects with type 2 diabetes, and 19% of nondiabetes subjects Vascular Health and Risk Management 2010:6 
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died during the follow-up period. The adjusted hazard ratio 
for type 1 diabetics vs nondiabetics was 3.6 (95% CI 2.2–5.7) 
in men and 13.3 (95% CI 6.9–22.5) in women. For type 2 
diabetics vs nondiabetics, the adjusted hazard ratio was 3.3 
(95% CI 2.5–4.5) in men and 10.1 (95% CI 6.7–17.4) in 
women. Similar results were found by the Renfrew Paisley 
survey with 25 years of follow-up of 15,406 patients.5 Goraya 
et al in a population based autopsy study, noted similar 
cardiovascular autopsy findings in non-diabetes patients with 
known ischemic heart disease compared to diabetes patients 
with no known ischemic heart disease, further emphasizing 
the role of diabetes as a coronary artery disease risk factor 
equivalent.6
Given these findings, there has been much interest in 
altering the inherent CV risk in diabetics through alteration of 
their metabolic profile. TZDs have been of particular interest 
due to the recognized pleiotrophic effects above and beyond 
lowering plasma glucose levels. In this article, we will review 
the effect of diabetes in the pathobiology of atherosclerosis, 
molecular and vascular biology of TZDs, as well as the 
clinical imaging studies looking at progression or regression 
of atherosclerosis in patients treated with glitazones.
Pathobiology of atherosclerosis
Mechanisms leading to increased atherosclerotic risk in 
patients with diabetes continue to be discovered. Obesity 
frequently precedes the development of insulin resistance 
and diabetes.7 High fat diets in animal models potentiate 
endothelial derived contracting factor (EDCF) mediators lead-
ing to the formation of increased levels of free radicals and 
pronounced up regulation of vascular thromboxane prostanoid 
receptor gene. These two changes weaken the protective role 
of the endothelium with reduced nitric oxide production and 
enhanced responsiveness to endothelin.8,9,10 Summarizing these 
findings, Traupe et al advocate that obesity related increases 
in production of EDCFs may contribute to the development of 
vascular diseases. As insulin resistance advances and patients 
develop diabetes, comparable vascular abnormalities are 
present at the endothelial level11,12 (see Figure 1).
Subjects with type 2 diabetes mellitus are at high risk 
for the development of atherosclerosis. An essential event 
in the growth of atherosclerosis is macrophage foam cell 
formation. Burke et al studied the morphology of diabetes 
plaques postmortem and found a strong positive association 
of increased macrophage infiltrate that was independent of 
cholesterol levels and patient age.13 The necrotic core size or 
macrophage infiltrate was significantly increased in diabetic 
subjects compared to nondiabetics with or without hyperlip-
idemia (P  0.002). In addition, the removal of cholesterol 
by macrophages plays a vital role in macrophage foam cell. 
Mauldin et al studied blood samples collected from diabetes 
patients for regulation of cholesterol efflux by ATP-binding 
cassette (ABC) transporters ABCA1 and ABCG1. Macro-
phages from subjects with type 2 diabetes mellitus had a 30% 
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diminution in cholesterol efflux to high density lipoprotein 
(HDL) or Apo A1 with an analogous 60% increase in choles-
terol accumulation relative to control subjects. This reduction 
in cholesterol efflux in type 2 diabetes patients is additive to 
the already amplified risk of atherosclerosis.
Intravascular ultrasound studies (IVUS) from Hong et al 
found that diabetes patients presenting with acute coro-
nary syndrome (ACS), had a higher incidence of multiple 
plaque ruptures (60% vs 29% non-diabetes, P  0.001) and 
thrombus (72% vs 52% non-diabetes, P  0.032) by IVUS 
than non-diabetes patients. A significant correlation with 
increased necrotic core volumes and thin cap fibroatheroma 
in the diabetes subset.14
Basic research is very important and its ties to clinical 
practice always are highly sought after. Recently, the 
ATHEROMA trial studied macrophages using iron oxide 
in humans given atorvastatin.15 Historically, increases in 
macrophage infiltration increase the risk of plaque rupture 
consequently detecting macrophage activity and inflamma-
tion within the atheroma could help discriminate stable plaque 
from vulnerable plaques. To evaluate macrophage activity, 
Tang et al randomized 47 patients with carotid stenosis by 
carotid ultrasound who had plaque accumulation on MRI to 
atorvastatin 10 mg or 80 mg for 12 weeks. The primary end 
point definition was a change from baseline in signal intensity 
on the ultrasmall superparamagnetic iron-oxide-(USPIO)-
enhanced MRI. Twenty patients completed the study, finding 
a significant reduction from baseline in signal intensity, the 
USPIO-enhanced MRI definition of plaque inflammation, in 
the high-dose atorvastatin arm at 6 and 12 weeks, while the 
patients treated with atorvastatin 10 mg showed no significant 
difference. This type of research is extremely important to 
further understanding of types of treatments that may regress 
plaque and reduce clinical events.
In summary, histology, metabolic changes and imaging 
studies all point toward a much higher risk for atherosclerosis 
development and CVD risk in patients with diabetes.
Molecular and vascular biology  
of glitazones
By definition the TZDs (glitazones) act by binding 
to peroxisome proliferator-activated receptors (PPARs), a 
group of receptor molecules inside the cell nucleus, specifi-
cally PPARγ/α/β/δ. The ligands for these receptors are 
free fatty acids (FFAs) and eicosanoids. When activated, the 
receptor migrates to the DNA, activating transcription of a 
number of specific genes. These nuclear changes have far 
reaching affects on metabolic status in patients. Issemann 
and Green discovered the mechanism by which peroxisome 
proliferation in the liver was induced by hypolipidemic drugs.16 
The discovery of this mechanism in 1990 led to the rapid 
development of many compounds in an attempt to improve the 
metabolic profile of primarily diabetes patients (Figure 2).
In general PPARα agonist (fibrates) improved the dys-
lipidemic profile in patients by lowering triglycerides (TG) 
and increasing HDL. Unfortunately, large pivotal trails 
(Fenofibrate Intervention and Event Lowering in Diabetes 
(FIELD)) did not demonstrate positive primary endpoints, 
although secondary cardiovascular endpoints were more 
favorable.17 Fenofibrate failed to significantly reduce the 
risk of the primary outcome, coronary events. It did reduce 
total cardiovascular events, mainly due to fewer non-fatal 
myocardial infarctions and revascularizations. The placebo 
arm had an increased rate of statin initiation, which might 
have masked a moderately larger treatment benefit.
Other basic science studies have found that fibrates could 
increase plasma homocysteine levels that occur through a 
PPARα-dependent mechanism and could reduce hepatic 
apo-AI production, by decreasing PPARα activity.18,19 On the 
contrary other indirect beneficial effects of PPARα are sug-
gestive from pioglitazone in the PROactive36 and PERISCOPE 
studies that demonstrated increases in HDL with reduction 
in triglycerides.20 In a head-to-head clinical trial and meta-
analysis, pioglitazone decreased TG significantly while this 
was not seen with rosiglitazone.21,22 Recently reported, pio-
glitazone increased IkBa expression in a PPARα-dependent 
manner potentially increasing expression of PPARα target 
genes in subcutaneous fat.23, 24 Rosiglitazone had no effects 
on PPARα activation.22 However rosiglitazone has shown 
a reduction in restenosis after coronary artery stenting and 
MMP-9 in type 2 diabetes patients.25,26
PPAR gamma ligands (thiazolidinediones (TZDs)) are the 
primary drugs used in type 2 diabetes for improving insulin 
sensitivity in skeletal muscle. The beneficial effects of TZDs 
on insulin sensitization effects are via the activation of PPARγ 
in adipose tissue, resulting in improved insulin sensitivity 
in skeletal muscle and liver. Human studies support PPARγ 
mRNA expression in human skeletal muscle is acutely regu-
lated by insulin and is augmented in both obese non-diabetes 
and type II diabetes subjects in direct relation to BMI and 
fasting insulin levels.27 These abnormalities of PPARγ are in 
part involved in skeletal muscle insulin resistance of obesity 
and type II diabetes. PPARγ induces subcutaneous adipocyte 
differentiation and reduces the visceral-to-subcutaneous 
adipose tissue ratio, which help to store free fatty acids in a 
less harmful subcutaneous location.Vascular Health and Risk Management 2010:6 
Wyatt et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
PPARβ/δ is a new exciting area of research. This PPAR 
isoform has only recently been studied because of its ubiqui-
tous nature. Its major efforts are focused in lipid uptake and 
anti-inflammatory roles. In several animal models of obesity 
and diabetes, these compounds increase HDL cholesterol and 
decrease white adipose tissue fat deposits. They have been 
found to reduce triglycerides, small dense LDL, and improve 
fasting insulin.28,29
In summary, in vitro research suggests that PPARs exert 
anti-atherogenic effects by inhibiting the expression of pro-
inflammatory genes and enhancing cholesterol efflux via 
activation of the liver X receptor–ABCA1 (LXR-ABCA1) 
pathway. Foam cell formation is a major therapeutic target 
in atherosclerosis. Basic cell research by Li et al found that 
PPARα and PPARγ agonists inhibited foam-cell formation 
in vivo through distinct ABCA1-independent pathways with 
stimulation of HDL cholesterol efflux.30 These findings from 
basic science would suggest a clinical benefit of TZDs in 
reducing atherosclerosis.
Glitazones and CV imaging  
of atherosclerosis
There are few things that influence humans more than a good 
illustrative picture. IVUS or imaging of the human coronary 
for atherosclerosis is probably very similar. One of the most 
impressive changes that come to mind is the research trial 
REVERSAL. The trial evaluated intensive lipid-lowering 
treatment (atorvastatin) vs moderate lipid-lowering regimen 
(pravastatin). The primary end point of the REVERSAL study 
was percent change in atheroma volume, which showed a 
2.7% significant increase in the pravastatin group and a 0.4% 
nonsignificant reduction in the atorvastatin group (P  0.02). 
This changed, to a large degree, many physicians view of 
statins in atherosclerosis treatment. The visual impact from 
the IVUS image was very impressive.
Studies with the glitazones are equally impressive. The 
studies to follow are completed in patients with type 2 dia-
betes who are considered as a coronary heart disease risk 
equivalent.
An important factor in the trials to follow is that in most 
of these trials patients were on statins and antiplatelet agents 
representative of the current high level of cardiovascular 
and diabetes care. The addition of the glitazones to these 
patients already on maximal cardiovascular treatment will 
be important when considering the results.
PERISCOPE was one of the first large randomized 
landmark glitazones IVUS trials. It enrolled 543 patients 
with type 2 diabetes who had baseline IVUS of the coronary 
PPARα PPARγ
PPARβ/δ
LIPIDS/Anti-INFLAMMATION
GLUCOSE METABOLISM LIPID METABOLISM
Figure  Peroxisome proliferative activated receptors (PPARs) clinical overview. This figure shows the overlapping activity of the PPARs. Clinically the current glucose-lowering 
agents and insulin sensitizers are PPARγ. PPARα compounds are primarily fibrates that reduce triglyceride levels and increase high-density lipoprotein cholesterol. PPARβ/δ 
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artery and then were randomized to receive either glimepiride 
(1–4 mg) or pioglitazone (15–45 mg) for 18 months, at which 
time IVUS studies were repeated. The primary endpoint 
found that the mean percent atheroma volume decreased 
by 0.16% in pioglitazone-treated subjects but increased by 
0.73% in glimepiride-treated patients. The use of statins in 
this trial was greater than 80% with 90% aspirin use. Both 
agents reduced HbA1c and fasting insulin levels, although 
pioglitazone’s effects on these end points were statistically 
greater. Pioglitazone also produced statistically beneficial 
changes in HDL and TG levels. In the pioglitazone group, 
compared with glimepiride, HDL levels increased 5.7 mg/dL 
(95%CI, 4.4 to 7.0 mg/dL; 16.0%) vs 0.9 mg/dL (95% 
CI, −0.3 to 2.1 mg/dL; 4.1%), and median TG levels decreased 
16.3 mg/dL (95% CI, −27.7 to −11.0 mg/dL; 15.3%) vs an 
increase of 3.3 mg/dL (95% CI,−10.7 to 11.7 mg/dL; 0.6%) 
(P  0.001 for both comparisons).31
APPROACH randomized 672 patients with type 2 
diabetes and indications for coronary angiography or PCI, 
at least 1 clinically significant coronary lesion, and 10% to 
50% narrowing of at least 1 untreated coronary artery. 333 
were randomized to rosiglitazone at up to 8 mg/day and 339 
patients who received glipizide at 15 mg/day. Aspirin use was 
about 84%, beta blockers in 67%, angiotensin-converting 
enzyme (ACE) inhibitors or angiotensin-receptor blockers in 
about 74%, and statins in about 80%. The primary analysis 
from baseline to 18 months follow up found the percent 
atheroma volume was not significantly different between 
the treatment groups. A decrease of atheroma volume was 
seen by –0.21% in rosiglitazone-treated subjects with an 
increase by +0.43% in glipizide-treated patients (P = 0.12). 
Hypoglycemia was more common the glipizide arm 28% vs 
8% with rosiglitazone (P  0.0001). In summary, the primary 
endpoint was unremarkable, however the results imply that 
rosiglitazone could be antiatherosclerotic but it did not appear 
to be proatherosclerotic.32,33
What accounts for the difference between these two 
imaging trials is unclear at present. Metabolics of the two 
compounds are different in relation to HDL and triglycer-
ides from Goldberg et al and may affect plaque biology.34 
The comparative drugs used in the trial are different and the 
duration of diabetes is different (see Figure 3 and Table 1). 
The anti-inflammatory aspects could play a role but at present 
there is no clear explanation why the results were different. 
Two different IVUS control labs were used, both very well 
known with high quality work. Amount of atherosclerotic 
burden and type of plaque biology could be different but 
unknown at present. Longstanding prior statin treatment in 
some groups may have already reduced soft plaque that more 
easily is removed. More basic research on plaque biology is 
required. Another important comment concerning these two 
trials is a possible lack of significant difference between the 
rosiglitazone and comparator in the APPROACH was due 
to a better outcome in the group treated with comparator 
(glipizide), as opposed to the effect observed in PERISCOPE, 
where the group treated with glimepiride fared worse. 
The mean percent atheroma volume decrease 0.16% with 
pioglitazone and 0.21% with rosiglitazone appear rather 
comparable. It should be noted that in PERISCOPE glime-
peride increased it by 0.73% while in APPROACH glipizide 
increased it only 0.43%. Thus it is possible for the difference 
between the two studies was in the different effects of the 
comparator drugs rather than the TZDs.
Other considerations of vascular imaging of the human 
carotid are helpful in evaluation of atherosclerosis. Two large 
trials related to the glitazones have been completed.
The most recent study reported was involving patients with 
pre-diabetes but without clinical evidence for CVD. STARR 
(STudy of Atherosclerosis with Ramipril and Rosiglitazone), 
a sub-study of the DREAM (Diabetes REduction Assessment 
with ramipril and rosiglitazone Medication) trial with 1425 
subjects intended at assessing the effects of the ACE inhibi-
tor ramipril and the TZD rosiglitazone on the progression of 
carotid intima-media thickness (CIMT). Using a 2 × 2 facto-
rial design subjects were randomized to ramipril 15 mg/day 
or its placebo and to rosiglitazone 8 mg/day or its placebo. 
The primary study outcome was the annualized change of 
the aggregate maximum CIMT, computed as the average of 
the maximum CIMTs across 12 carotid arterial segments. 
A secondary endpoint of annualized change of the mean far 
wall left and right common CIMT. Median follow-up was 
3 years and carotid ultrasound examinations were obtained 
at baseline and yearly thereafter. Rosiglitazone decreased 
glycemia with a mild reduction in blood pressure and modest 
favorable effects on CIMT progression. Compared with pla-
cebo, rosiglitazone reduced the primary CIMT outcome, but 
the difference was not statistically significant. The primary 
outcome aggregate maximum CIMT was 0.00063 mm/year 
for the rosiglitazone arm and 0.0090 mm/year for placebo 
(difference –0.0027 P = 0.08).
The CHICAGO study was a randomized, double-blind, 
comparator-controlled trial from the Chicago metropolitan 
area at 28 clinical sites. 462 patients with type 2 diabetes 
were randomized to receive 72 weeks of treatment with 
pioglitazone, or glimepiride, titrated to the HbA1c target. 
Patients had a mean duration of diabetes of 7.7 years and Vascular Health and Risk Management 2010:6 
Wyatt et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
a mean HbA1c value of 7.4%. 55% of both groups were 
receiving statins. CIMT images were captured by a single 
ultrasonographer at one center and read by a single reader 
blinded to treatment assignment using automated edge-
detection technology. The main outcome measure was the 
absolute change from baseline to the final visit at 72 weeks 
in the mean posterior-wall CIMT of the left and right 
common carotid arteries. The results found the CIMT was 
less with pioglitazone than it was with glimepiride at all 
time points – weeks 24, 48, and 72. The primary end point 
of progression of mean CIMT was less with pioglitazone, 
with a difference between groups of 0.013 mm, favoring 
the pioglitazone group (95% CI –0.013 [–0.024 to 0.002]; 
P  0.02).35
Human trials
PERISCOPE REVERSAL ASTEROID
0.73
2.7
P
l
a
c
e
b
o
0.14
−0.16
P
i
o
g
l
i
t
a
z
o
n
e −1.06
−0.4
A
t
o
r
v
a
s
t
a
t
i
n
−0.98
−0.21
R
o
s
i
g
l
i
t
a
z
o
n
e
P < 0.002 P < 0.02 P < 0.001
P < 0.001 P = NS P = NS
APO A-1 Milano CAMELOT APPROACH
0.5
0.8
1.3
0.43
G
l
i
p
i
z
i
d
e
P
r
o
g
r
e
s
s
i
o
n
R
e
g
r
e
s
s
i
o
n
Atherosclerosis
3
2.5
2
1.5
1
0.5
0
−0.5
−1
−1.5
P
e
r
c
e
n
t
 
a
t
h
e
r
o
m
a
 
v
o
l
u
m
e
P
l
a
c
e
b
o
A
C
E
 
i
n
h
i
b
i
t
o
r
C
a
l
c
i
u
m
 
c
h
a
n
n
e
l
 
b
l
o
c
k
e
r
Figure  intravascular ultrasound studies change from baseline in percent atheroma volume.
Table  Trial demographics and imaging results
Trial ACS Chronic CAD DM ASA Statin Results Comment
ASTeROiD-iVUS √ 80% Rosuvastatin 40 mg ++++ No comparator arm
PeRiSCOPe-iVUS √ 90% 80% +++ (Pioglitazone) Glimepiride vs 
Pioglitazone
ReVeRSAL-iVUS √ 32% ++ (Atorvastatin 80) Atorvastatin 80 vs 
Pravastatin 40
ApoA1 Milano-iVUS √ 30% placebo  
50% eTC-216
++++
APPROACH-iVUS √ P = NS Rosiglitazone vs 
Glipizide
Abbreviations: ACS, acute coronary syndrome;   ASA, aspirin; CAD, coronary artery disease; DM, diabetes mellitus; iVUS, intravascular ultrasound.Vascular Health and Risk Management 2010:6 
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The CIMT results between STARR and CHICAGO are 
different. The types of patients are different between these 
two studies, CHICAGO used type 2 diabetes patients and 
STARR was pre-diabetes patients. Use of other medication 
may impact the results and drug combinations choices can 
affect plaque biology. The consistent beneficial findings 
with pioglitazone from PERISCOPE and CHICAGO merits 
a closer look at this type of TZD. The inconsistency from 
rosiglitazone in the trials is disturbing; however the trials are 
different in design, patient characteristics, and drug combina-
tions used. All of these differences make it very hard to make 
strong statements or recommendations.
In summary, imaging trials are not perfect for answering 
many of our questions concerning glitazones in patients with 
pre-diabetes or type 2 diabetes. Most importantly they do not 
fully answer the main question: do they reduce cardiovascular 
clinical events, or regression of atherosclerosis will remain 
unanswered for now, requiring future studies. In closing two 
large studies have attempted to answer the cardiovascular 
question related to glitazones. PROactive trial36 enrolled 
5238 patients with type 2 diabetes who had evidence of 
macrovascular disease in a prospective, randomized study. 
The primary endpoint included a composite of endovascular 
or surgical intervention in the coronary or leg arteries, and 
amputation above the ankle, all-cause mortality, non-fatal 
myocardial infarction (including silent myocardial infarction), 
stroke, acute coronary syndrome. The primary endpoint was 
not met (hazard ratio 0.90, 95% CI 0.80–1.02, P = 0.095) 
primarily due to leg revascularization. The principle secondary 
endpoint was a composite of all-cause mortality, non-fatal 
myocardial infarction, and stroke (0.84, 0.72–0.98, P = 0.027). 
This study has been one of the most controversial studies 
related to TZDs and still is unresolved from main points 
of view. Many of the sub-studies are very positive toward 
pioglitazone, with consistent trends in a favorable direction; 
however the primary study missed its endpoint. On the heels 
of this large TZD trial is RECORD,37 which was a multicenter, 
open-label trial, in which 4447 patients with type 2 diabetes 
on metformin or sulfonylurea monotherapy with mean HbA1c 
of 7.9% were randomly assigned to addition of rosiglitazone 
(n = 2220) or to a combination of metformin and sulfonylurea 
(active control group, n = 2227). The primary endpoint was 
cardiovascular hospitalization or cardiovascular death, with 
a hazard ratio non-inferiority margin of 1.20. Analysis was 
by intention to treat. The primary outcome during a mean 
5⋅5-year follow-up, met non-inferiority criteria (hazard ratio 
0.99, 95% CI 0.85–1.16). Specific to cardiovascular death 
the HR was 0.84 (0.59–1.18), and for myocardial infarction 
was 1.14 (0.80–1.63), and 0.72 (0.49–1.06) for stroke. Both 
of these trials reported increased heart failure concerns and 
bone fractures that made things even more difficult with 
these compounds. Currently, the controversy still continues 
to be a hotly debated topic on both sides and unlikely to be 
resolved in time.
In closing, the future is bright for many other imaging 
modalities from research that have not been included due to 
the current studies did not use this type of equipment. For 
imaging from inside the coronary tree, the current resolu-
tion of IVUS is around 150 microns; however soon, with 
radiolabeling, the use of optical coherence tomography at 5 
microns may offer substantial advantage to our understanding 
of atherosclerosis.38
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